PerkinElmer, Inc.
Aug 4, 2016
PDF

PerkinElmer Announces Financial Results for the Second Quarter of 2016

WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today reported financial results for the second quarter ended July 3, 2016.

The Company reported GAAP earnings per share from continuing operations of $0.56, as compared to $0.43 in the second quarter of 2015. GAAP revenue in the second quarter of 2016 was $572.7 million, as compared to $563.9 million in the comparable period of 2015. GAAP operating income from continuing operations for the second quarter of 2016 was $71.2 million, as compared to $68.1 million in the second quarter of 2015. Operating profit margin was 12.4% as a percentage of revenue, as compared to 12.1% for the same period a year ago.

Adjusted earnings per share was $0.67, as compared to $0.60 in the second quarter of 2015. Adjusted revenue for the quarter was $572.8 million, as compared to $564.1 million in the second quarter of 2015. Adjusted operating income for the second quarter of 2016 was $100.1 million, as compared to $95.8 million for the same period a year ago. Adjusted operating profit margin was 17.5% as a percentage of adjusted revenue, as compared to 17.0% for the same period a year ago. Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

"I am pleased to report that PerkinElmer had a strong second quarter and year-to-date financial performance, as improved execution drove substantial margin expansion and cash flow generation while also funding a number of strategic growth investments," said Robert Friel, chairman and chief executive officer of PerkinElmer. "We believe these investments, coupled with the strength of our productivity and efficiency initiatives, position us well to deliver solid financial results for the balance of 2016."

Cash Flow

For the first six months of 2016, GAAP operating cash flow from continuing operations was $125.7 million, as compared to $101.2 million in the comparable period of 2015.

Financial Overview by Reporting Segment for the Second Quarter of 2016

Human Health

Environmental Health

Reiterates Financial Guidance - Full Year 2016

For the full year 2016, the Company reiterates its previous guidance of GAAP earnings per share from continuing operations in the range of $2.29 to $2.39 and on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $2.75 to $2.85.

Conference Call Information

The Company will discuss its second quarter results and its outlook for business trends in a conference call on August 4, 2016 at 5:00 p.m. Eastern Time. To access the call, please dial (541) 797-2422 prior to the scheduled conference call time and provide the access code 43736451.

A live audio webcast of the call will be available on the Investor section of the Company's Web site, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company's Web site for a two week period beginning approximately two hours after the call.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in the prospectus supplement for our most recent senior notes offering that we filed with the Securities and Exchange Commission on July 14, 2016. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.3 billion in 2015, has about 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

 
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
         
 

Three Months Ended

Six Months Ended

(In thousands, except per share data)

July 3, 2016

June 28, 2015

July 3, 2016

June 28, 2015

 
 
Revenue $ 572,667 $ 563,906 $ 1,111,351 $ 1,090,807
 
Cost of revenue 307,384 311,394 595,971 602,921
Selling, general and administrative expenses 153,994 146,742 301,539 292,615
Research and development expenses 35,007 32,683 68,792 64,803
Restructuring and contract termination charges, net   5,089     4,956     5,089     4,956  
 
Operating income from continuing operations 71,193 68,131 139,960 125,512
 
Interest income (127 ) (132 ) (237 ) (341 )
Interest expense 9,939 9,302 19,780 18,690
Gain on disposition of businesses and assets, net (5,562 ) - (5,562 ) -
Other expense, net   1,143     1,673     2,498     1,915  
 
Income from continuing operations, before income taxes 65,800 57,288 123,481 105,248
 
Provision for income taxes   4,578     8,292     14,754     15,941  
 
Income from continuing operations 61,222 48,996 108,727 89,307
 
Gain (loss) from discontinued operations, before income taxes - 35 - (2 )
Loss on disposition of discontinued operations, before income taxes (8 ) (10 ) (11 ) (23 )
(Benefit from) provision for income taxes on discontinued operations and dispositions   (2,643 )   47     (2,607 )   (26 )
 
Gain (loss) from discontinued operations and dispositions   2,635     (22 )   2,596     1  
 
Net income $ 63,857   $ 48,974   $ 111,323   $ 89,308  
 
 
Diluted earnings per share:
Income from continuing operations $ 0.56 $ 0.43 $ 0.98 $ 0.79
 
Gain (loss) from discontinued operations and dispositions   0.02     (0.00 )   0.02     0.00  
 
Net income $ 0.58   $ 0.43   $ 1.01   $ 0.79  
 
 
Weighted average diluted shares of common stock outstanding 109,844 113,833 110,520 113,636
 
 
ABOVE PREPARED IN ACCORDANCE WITH GAAP
 
                   
Additional Supplemental Information (1):
(per share, continuing operations)
 
GAAP EPS from continuing operations $ 0.56 $ 0.43 $ 0.98 $ 0.79
Amortization of intangible assets 0.17 0.17 0.34 0.35
Purchase accounting adjustments 0.04 0.02 0.06 0.06

Gain on disposition of businesses and assets, net

(0.05 ) - (0.05 ) -
Mark to market on postretirement benefits - 0.01 (0.00 ) 0.01
Restructuring and contract termination charges 0.05 0.04 0.05 0.04
Tax on above items   (0.10 )   (0.08 )   (0.17 )   (0.16 )
Adjusted EPS $ 0.67   $ 0.60   $ 1.22   $ 1.10  
 

(1) amounts may not sum due to rounding

             
PerkinElmer, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
 
 
 

Three Months Ended

Six Months Ended

(In thousands, except percentages) July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015
 
 
Human Health Reported revenue $ 353,477 $ 341,488 $ 685,919 $ 667,541
Purchase accounting adjustments   176     195     351     464  
Adjusted Revenue   353,653     341,683     686,270     668,005  
 
Reported operating income from continued operations 57,592 60,531 112,319 116,413
OP% 16.3 % 17.7 % 16.4 % 17.4 %
Amortization of intangible assets 13,675 15,270 27,446 30,743
Purchase accounting adjustments 4,512 225 6,037 525
Acquisition-related costs 82 137 425 209
Restructuring and contract termination charges, net   4,311     1,820     4,311     1,820  
Adjusted operating income   80,172     77,983     150,538     149,710  
Adjusted OP% 22.7 % 22.8 % 21.9 % 22.4 %
 
Environmental Health Reported revenue 219,190 222,418 425,432 423,266
 
Reported operating income from continued operations 25,596 19,422 51,193 30,768
OP% 11.7 % 8.7 % 12.0 % 7.3 %
Amortization of intangible assets 5,219 4,583 10,486 8,948
Purchase accounting adjustments 264 1,617 398 6,467
Acquisition-related costs 79 93 102 216
Restructuring and contract termination charges, net   778     3,136     778     3,136  
Adjusted operating income   31,936     28,851     62,957     49,535  
Adjusted OP% 14.6 % 13.0 % 14.8 % 11.7 %
 
Corporate Reported operating (loss) income (11,995 ) (11,822 ) (23,552 ) (21,669 )
Mark to market on postretirement benefits   -     832     (3 )   1,066  
Adjusted operating loss   (11,995 )   (10,990 )   (23,555 )   (20,603 )
 
 
Continuing Operations Reported revenue $ 572,667 $ 563,906 $ 1,111,351 $ 1,090,807
Purchase accounting adjustments   176     195     351     464  
Adjusted Revenue   572,843     564,101     1,111,702     1,091,271  
 
Reported operating income from continued operations 71,193 68,131 139,960 125,512
OP% 12.4 % 12.1 % 12.6 % 11.5 %
Amortization of intangible assets 18,894 19,853 37,932 39,691
Purchase accounting adjustments 4,776 1,842 6,435 6,992
Acquisition-related costs 161 230 527 425
Mark to market on postretirement benefits - 832 (3 ) 1,066
Restructuring and contract termination charges, net   5,089     4,956     5,089     4,956  
Adjusted operating income $ 100,113   $ 95,844   $ 189,940   $ 178,642  
Adjusted OP% 17.5 % 17.0 % 17.1 % 16.4 %
 

REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

     
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
 
(In thousands)

July 3, 2016

January 3, 2016

 
Current assets:
Cash and cash equivalents $ 248,083 $ 237,932
Accounts receivable, net 435,822 439,015
Inventories, net 300,262 288,028
Other current assets   94,780     68,186  
Total current assets   1,078,947     1,033,161  
 
Property, plant and equipment:
At cost 508,953 494,956
Accumulated depreciation   (341,757 )   (327,927 )
Property, plant and equipment, net 167,196 167,029
Marketable securities and investments 1,448 1,586
Intangible assets, net 454,407 490,811
Goodwill 2,272,202 2,276,149
Other assets, net   219,796     197,559  
Total assets $ 4,193,996   $ 4,166,295  
 
Current liabilities:
Current portion of long-term debt $ 1,147 $ 1,123
Accounts payable 156,442 152,726
Short-term accrued restructuring and contract termination charges 11,492 17,090
Accrued expenses and other current liabilities 390,000 388,446
Current liabilities of discontinued operations   2,100     2,100  
Total current liabilities   561,181     561,485  
 
Long-term debt 1,056,934 1,011,762
Long-term liabilities   487,678     482,607  
Total liabilities   2,105,793     2,055,854  
 
Total stockholders' equity   2,088,203     2,110,441  
Total liabilities and stockholders' equity $ 4,193,996   $ 4,166,295  
 

PREPARED IN ACCORDANCE WITH GAAP

 
PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
         
 

Three Months Ended

Six Months Ended

July 3, 2016

June 28, 2015

July 3, 2016

June 28, 2015

(In thousands)
 
Operating activities:
Net income $ 63,857 $ 48,974 $ 111,323 $ 89,308
(Gain on) loss from discontinued operations, net of income taxes   (2,635 )   22       (2,596 )   (1 )
Income from continuing operations   61,222     48,996       108,727     89,307  
Adjustments to reconcile income from continuing operations
to net cash provided by continuing operations:
Restructuring and contract termination charges, net 5,089 4,956 5,089 4,956
Depreciation and amortization 26,439 28,259 53,396 56,593
Stock-based compensation 5,958 4,206 9,911 8,193
Amortization of deferred debt financing costs and accretion of discounts 395 365 751 677
Gain from disposition of businesses and assets, net (5,562 ) - (5,562 ) -
Amortization of acquired inventory revaluation 265 1,617 396 6,467

Changes in assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:

Accounts receivable, net (6,211 ) (6,739 ) 6,233 30,843
Inventories 9,141 (10,829 ) (6,639 ) (33,327 )
Accounts payable (1,715 ) 10,794 2,501 (1,541 )
Accrued expenses and other   (1,419 )   (18,113 )     (49,121 )   (61,007 )
Net cash provided by operating activities of continuing operations 93,602 63,512 125,682 101,161
Net cash provided by (used in) operating activities of discontinued operations   2,635     (42 )     2,596     (27 )
Net cash provided by operating activities   96,237     63,470       128,278     101,134  
 
Investing activities:
Capital expenditures (8,512 ) (5,620 ) (16,320 ) (10,099 )
Proceeds from surrender of life insurance policies 44 - 44 -
Changes in restricted cash balances (2,000 ) - (2,000 ) 59
Proceeds from disposition of businesses 20,000 - 21,000 -
Activity related to acquisitions and investments, net of cash and cash equivalents acquired   -     (14,116 )     (10,484 )   (18,735 )
Net cash provided by (used in) investing activities   9,532     (19,736 )     (7,760 )   (28,775 )
 
Financing Activities:
Payments on revolving credit facility (120,000 ) (151,000 ) (195,000 ) (249,000 )
Proceeds from revolving credit facility 57,000 123,000 240,000 184,000
Settlement of cash flow hedges (1,352 ) 7,905 1,278 23,468
Net (payments on) proceeds from other credit facilities (278 ) 608 (553 ) 344
Payments for acquisition-related contingent consideration (6 ) - (99 ) -
Proceeds from issuance of common stock under stock plans 7,715 3,829 8,953 12,669
Purchases of common stock (192 ) (141 ) (151,544 ) (4,095 )
Dividends paid   (7,631 )   (7,923 )     (15,474 )   (15,799 )
Net cash used in financing activities   (64,744 )   (23,722 )     (112,439 )   (48,413 )
 
Effect of exchange rate changes on cash and cash equivalents   (3,673 )   3,234       2,072     (6,597 )
 
Net increase in cash and cash equivalents 37,352 23,246 10,151 17,349
Cash and cash equivalents at beginning of period   210,731     168,924       237,932     174,821  
Cash and cash equivalents at end of period $ 248,083   $ 192,170     $ 248,083   $ 192,170  
 

PREPARED IN ACCORDANCE WITH GAAP

 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
     
(In millions, except per share data and percentages)

PKI

Three Months Ended

July 3, 2016

 

June 28, 2015

   
Adjusted revenue:
Revenue $ 572.7 $ 563.9
Purchase accounting adjustments   0.2           0.2      
Adjusted revenue $ 572.8         $ 564.1      
 
Adjusted gross margin:
Gross margin $ 265.3 46.3 % $ 252.5 44.8 %
Amortization of intangible assets 8.4 1.5 % 10.8 1.9 %
Purchase accounting adjustments   0.5     0.1 %     1.8     0.3 %
Adjusted gross margin $ 274.1     47.9 %   $ 265.1     47.0 %
 
Adjusted SG&A:
SG&A $ 154.0 26.9 % $ 146.7 26.0 %
Amortization of intangible assets (10.3 ) -1.8 % (8.9 ) -1.6 %
Purchase accounting adjustments (4.3 ) -0.8 % (0.0 ) 0.0 %
Acquisition-related costs (0.2 ) 0.0 % (0.2 ) 0.0 %
Mark to market on postretirement benefits   -     0.0 %     (0.8 )   -0.1 %
Adjusted SG&A $ 139.2     24.3 %   $ 136.7     24.2 %
 
Adjusted R&D:
R&D $ 35.0 6.1 % $ 32.7 5.8 %
Amortization of intangible assets   (0.2 )   0.0 %     (0.1 )   0.0 %
Adjusted R&D $ 34.8     6.1 %   $ 32.6     5.8 %
 
Adjusted operating income:
Operating income $ 71.2 12.4 % $ 68.1 12.1 %
Amortization of intangible assets 18.9 3.3 % 19.9 3.5 %
Purchase accounting adjustments 4.8 0.8 % 1.8 0.3 %
Acquisition-related costs 0.2 0.0 % 0.2 0.0 %
Mark to market on postretirement benefits - 0.0 % 0.8 0.1 %
Restructuring and contract termination charges, net   5.1     0.9 %     5.0     0.9 %
Adjusted operating income $ 100.1     17.5 %   $ 95.8     17.0 %
             
PKI
Three Months Ended

July 3, 2016

June 28, 2015

 
Adjusted EPS:
GAAP EPS $ 0.58 $ 0.43
Discontinued operations, net of income taxes   0.02           (0.00 )    
GAAP EPS from continuing operations 0.56 0.43
Amortization of intangible assets 0.17 0.17
Purchase accounting adjustments 0.04 0.02
Acquisition-related costs 0.00 0.00
Gain on disposition of businesses and assets, net (0.05 ) -
Mark to market on postretirement benefits - 0.01
Restructuring and contract termination charges 0.05 0.04
Tax on above items   (0.10 )         (0.08 )    
Adjusted EPS $ 0.67         $ 0.60      
             
Human Health
Three Months Ended

July 3, 2016

June 28, 2015

 
Adjusted revenue:
Revenue $ 353.5 $ 341.5
Purchase accounting adjustments   0.2           0.2      
Adjusted revenue $ 353.7         $ 341.7      
 
Adjusted operating income:
Operating income $ 57.6 16.3 % $ 60.5 17.7 %
Amortization of intangible assets 13.7 3.9 % 15.3 4.5 %
Purchase accounting adjustments 4.5 1.3 % 0.2 0.1 %
Acquisition-related costs 0.1 0.0 % 0.1 0.0 %
Restructuring and contract termination charges, net   4.3     1.2 %     1.8     0.5 %
Adjusted operating income $ 80.2     22.7 %   $ 78.0     22.8 %
             
Environmental Health
Three Months Ended

July 3, 2016

June 28, 2015

 
Revenue:
Revenue $ 219.2 $ 222.4
 
Adjusted operating income:
Operating income $ 25.6 11.7 % $ 19.4 8.7 %
Amortization of intangible assets 5.2 2.4 % 4.6 2.1 %
Purchase accounting adjustments 0.3 0.1 % 1.6 0.7 %
Acquisition-related costs 0.1 0.0 % 0.1 0.0 %
Restructuring and contract termination charges, net   0.8     0.4 %     3.1     1.4 %
Adjusted operating income $ 31.9     14.6 %   $ 28.9     13.0 %
 

(1) amounts may not sum due to rounding

 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
                 
(In millions, except per share data and percentages) PKI
Six Months Ended

July 3, 2016

 

June 28, 2015

 
Adjusted revenue:
Revenue $ 1,111.4 $ 1,090.8
Purchase accounting adjustments   0.4           0.5      
Adjusted revenue $ 1,111.7         $ 1,091.3      
 
Adjusted gross margin:
Gross margin $ 515.4 46.4 % $ 487.9 44.7 %
Amortization of intangible assets 16.9 1.5 % 21.5 2.0 %
Purchase accounting adjustments 0.8 0.1 % 7.0 0.6 %
Mark to market on postretirement benefits   (0.0 )   0.0 %     0.2     0.0 %
Adjusted gross margin $ 533.0     47.9 %   $ 516.6     47.3 %
 
Adjusted SG&A:
SG&A $ 301.5 27.1 % $ 292.6 26.8 %
Amortization of intangible assets (20.7 ) -1.9 % (17.9 ) -1.6 %
Purchase accounting adjustments (5.7 ) -0.5 % (0.0 ) 0.0 %
Acquisition-related costs (0.5 ) 0.0 % (0.4 ) 0.0 %
Mark to market on postretirement benefits   -     0.0 %     (0.8 )   -0.1 %
Adjusted SG&A $ 274.7     24.7 %   $ 273.4     25.1 %
 
Adjusted R&D:
R&D $ 68.8 6.2 % $ 64.8 5.9 %
Amortization of intangible assets   (0.4 )   0.0 %     (0.2 )   0.0 %
Adjusted R&D $ 68.4     6.2 %   $ 64.6     5.9 %
 
Adjusted operating income:
Operating income $ 140.0 12.6 % $ 125.5 11.5 %
Amortization of intangible assets 37.9 3.4 % 39.7 3.6 %
Purchase accounting adjustments 6.4 0.6 % 7.0 0.6 %
Acquisition-related costs 0.5 0.0 % 0.4 0.0 %
Mark to market on postretirement benefits (0.0 ) 0.0 % 1.1 0.1 %
Restructuring and contract termination charges, net   5.1     0.5 %     5.0     0.5 %
Adjusted operating income $ 189.9     17.1 %   $ 178.6     16.4 %
             
PKI
Six Months Ended

July 3, 2016

June 28, 2015

 
Adjusted EPS:
GAAP EPS $ 1.01 $ 0.79
Discontinued operations   0.02           0.00      
GAAP EPS from continuing operations 0.98 0.79
Amortization of intangible assets 0.34 0.35
Purchase accounting adjustments 0.06 0.06
Acquisition-related costs 0.00 0.00
Gain on disposition of businesses and assets, net (0.05 ) -
Mark to market on postretirement benefits (0.00 ) 0.01
Restructuring and contract termination charges 0.05 0.04
Tax on above items   (0.17 )         (0.16 )    
Adjusted EPS $ 1.22         $ 1.10      
             
PKI
Twelve Months Ended

January 1, 2017

Adjusted EPS: Projected
GAAP EPS from continuing operations

$2.29 - $2.39

Amortization of intangible assets

0.67

Purchase accounting adjustments

0.06

Gain on disposition of businesses and assets, net

(0.05

)

Mark to market on postretirement benefits

(0.00

)

Restructuring and contract termination charges

0.05

Tax on above items        

(0.27

)

 
Adjusted EPS        

$2.75 - $2.85

   
             
Human Health
Six Months Ended

July 3, 2016

June 28, 2015

 
Adjusted revenue:
Revenue $ 685.9 $ 667.5
Purchase accounting adjustments   0.4           0.5      
Adjusted revenue $ 686.3         $ 668.0      
 
Adjusted operating income:
Operating income $ 112.3 16.4 % $ 116.4 17.4 %
Amortization of intangible assets 27.4 4.0 % 30.7 4.6 %
Purchase accounting adjustments 6.0 0.9 % 0.5 0.1 %
Acquisition-related costs 0.4 0.1 % 0.2 0.0 %
Restructuring and contract termination charges, net   4.3     0.6 %     1.8     0.3 %
Adjusted operating income $ 150.5     21.9 %   $ 149.7     22.4 %
             
Environmental Health
Six Months Ended

July 3, 2016

June 28, 2015

 
Revenue:
Revenue $ 425.4 $ 423.3
 
Adjusted operating income:
Operating income $ 51.2 12.0 % $ 30.8 7.3 %
Amortization of intangible assets 10.5 2.5 % 8.9 2.1 %
Purchase accounting adjustments 0.4 0.1 % 6.5 1.5 %
Acquisition-related costs 0.1 0.0 % 0.2 0.1 %
Restructuring and contract termination charges, net   0.8     0.2 %     3.1     0.7 %
Adjusted operating income $ 63.0     14.8 %   $ 49.5     11.7 %
 

(1) amounts may not sum due to rounding

 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
   
 
PKI
Three Months Ended
July 3, 2016
Organic revenue growth:
Reported revenue growth 2%
Less: effect of foreign exchange rates -1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses -1%
Organic revenue growth 3%
 
 
Human Health
Three Months Ended
July 3, 2016
Organic revenue growth:
Reported revenue growth 4%
Less: effect of foreign exchange rates 0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses -2%
Organic revenue growth 6%
 
 
Environmental Health
Three Months Ended
July 3, 2016
Organic revenue growth:
Reported revenue growth -1%
Less: effect of foreign exchange rates -2%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 1%
Organic revenue growth -1%
 

(1) amounts may not sum due to rounding

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with U. S. generally accepted accounting principles ("GAAP"). However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term "adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "adjusted revenue growth" to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency translation and acquisitions, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We also exclude the impact of sales from divested businesses by deducting the effects of divested business revenue from the current and prior periods. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets, inventory fair value adjustments related to business acquisitions, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition-related expenses, significant litigation matters and significant environmental charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term "adjusted operating income," to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition-related costs, significant litigation matters, significant environmental charges, and restructuring and contract termination charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," or "adjusted operating margin" to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, other purchase accounting adjustments, acquisition-related costs, significant litigation matters, significant environmental charges, gain on disposition of businesses and assets, net, and restructuring and contract termination charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We also adjust for any tax impact related to the above items.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, other costs related to business acquisitions, significant litigation matters, significant environmental charges, adjustments for mark-to-market accounting on post-retirement benefits, gain on disposition of businesses and assets, restructuring and contract termination charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

PerkinElmer, Inc.
Investor Relations:
Tommy J. Thomas, CPA, 781-663-5889
tommy.thomas@perkinelmer.com
or
Media Contact:
Fara Goldberg, 781-663-5699
fara.goldberg@perkinelmer.com

Source: PerkinElmer, Inc.

News Provided by Acquire Media